A phase II trial investigating if bevacizumab in combination with hormone therapy will reverse acquired estrogen independence in metastatic breast cancer patients

Falkson, Carla I.; Rossman, J. F.; Nabell, L.; Jt, Carpenter; Saleh, Mansoor N.; O’Malley, Janis P.; Forero, Andres

doi:10.1200/jco.2008.26.15_suppl.1074

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MBC patients who had progressed on hormonal therapy after a previous response were included in a phase II trial in which bevacizumab was added to the anti-hormonal therapy. Results from this study (27 patients) showed no responses but SD in 66% of the patients (duration not reported) [ 26 ]. A phase II trial of bevacizumab plus letrozole in 32 postmenopausal women with hormone-receptor-positive advanced breast cancer (ABC) revealed 2 patients with PR and 13 with SD for 6 months or more [ 27 ].…”

Section: Inhibitors Of Vegf: Monoclonal Antibodiesmentioning

confidence: 99%

Antiangiogenic therapy for breast cancer

et al. 2010

View full text Add to dashboard Cite

Angiogenesis is an important component of cancer growth, invasion and metastasis. Therefore, inhibition of angiogenesis is an attractive strategy for treatment of cancer. We describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimal use of these agents for the treatment of breast cancer. Currently, the most promising approach has been the use of bevacizumab, a humanized monoclonal antibody directed against the most potent pro-angiogenic factor, vascular endothelial growth factor (VEGF). Small molecular inhibitors of VEGF tyrosine kinase activity, such as sorafenib, appear promising. While, the role of sunitinib and inhibitors of mammalian target of rapamycin (mTOR) in breast cancer has to be defined. Several unanswered questions remain, such as choice of drug(s), optimal duration of therapy and patient selection criteria.

show abstract

Section: Inhibitors Of Vegf: Monoclonal Antibodiesmentioning

confidence: 99%

Antiangiogenic therapy for breast cancer

et al. 2010

View full text Add to dashboard Cite

show abstract

Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast Cancer

Traina

Rugo

Caravelli

et al. 2010

JCO

View full text Add to dashboard Cite

Purpose Preclinical models suggest that the use of anti–vascular endothelial growth factor (anti-VEGF) therapy with antiestrogens may prevent or delay the development of endocrine therapy resistance. We therefore performed a feasibility study to evaluate the safety of letrozole plus bevacizumab in patients with hormone receptor–positive metastatic breast cancer (MBC). Methods Patients with locally advanced breast cancer or MBC were treated with the aromatase inhibitor (AI) letrozole (2.5 mg orally daily) and the anti-VEGF antibody bevacizumab (15 mg/kg intravenously every 3 weeks). The primary end point was safety, defined by grade 4 toxicity using the National Cancer Institute Common Toxicity Criteria, version 3.0. Secondary end points included response rate, clinical benefit rate, and progression-free survival (PFS). Prior nonsteroidal AIs (NSAIs) were permitted in the absence of progressive disease. Results Forty-three patients were treated. After a median of 13 cycles (range, 1 to 71 cycles), select treatment-related toxicities included hypertension (58%; grades 2 and 3 in 19% and 26%), proteinuria (67%; grades 2 and 3 in 14% and 19%), headache (51%; grades 2 and 3 in 16% and 7%), fatigue (74%; grades 2 and 3 in 19% and 2%), and joint pain (63%; grades 2 and 3 in 19% and 0%). Eighty-four percent of patients had at least stable disease on an NSAI, confounding efficacy results. Partial responses were seen in 9% of patients and stable disease ≥ 24 weeks was noted in 67%. Median PFS was 17.1 months. Conclusion Combination letrozole and bevacizumab was feasible with expected bevacizumab-related events of hypertension, headache, and proteinuria. Phase III proof-of-efficacy trials of endocrine therapy plus bevacizumab are in progress (Cancer and Leukemia Group B 40503).

show abstract

A phase II trial investigating if bevacizumab in combination with hormone therapy will reverse acquired estrogen independence in metastatic breast cancer patients

Cited by 2 publications

References 0 publications

Antiangiogenic therapy for breast cancer

Antiangiogenic therapy for breast cancer

Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast Cancer

Contact Info

Product

Resources

About